Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Authors
Noboru Yamamoto
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan;
Noboru Yamamoto , Anthony W. Tolcher , Navid Hafez , Iwona Lugowska , Rodryg Ramlau , Mrinal M. Gounder , Junxian Geng , Jian Li , Michael Teufel , Angela Maerten , Patricia LoRusso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03449381 and NCT03964233
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 543)
DOI
10.1200/JCO.2023.41.4_suppl.543
Abstract #
543
Poster Bd #
C13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
First Author: Teresa Macarulla
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of surufatinib in biliary tract cancer: Preliminary results of a real-world study.
First Author: Zongli Zhang
Poster
2023 ASCO Annual Meeting
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
First Author: Patricia LoRusso